London, 5th December 2016: Arthurian Life Sciences today welcomed the ‘highly encouraging’ findings of a significant clinical trial by ReNeuron, a global leader in the development of cell-based therapeutics.
The PISCES II trial monitored improvement in arm movement as measured by the ARAT sub-test number two.
The aim was to achieve discernible change within three months in two of the 21 patients receiving treatment. Three patients registered improvement over a variety of timescales. 15 patients in the 21-person study had a “clinically significant response” on at least one of the three commonly-used scales for assessing improvements following treatment.
ReNeuron now intends to apply to the US and European regulatory authorities to commence a randomised, placebo-controlled, pivotal clinical trial in patients who are living with disability post-stroke.
Arthurian Life Sciences manages the Wales Life Sciences Investment Fund which made a substantial investment in ReNeuron and attracted the company to Wales.
Professor Sir Christopher Evans, chairman and founder of Arthurian Life Sciences, said: “We are delighted that ReNeuron has reported such encouraging results from its latest study. The treatment has great potential for patients and the company will go into its next trial with confidence. The results of the PISCES II trial are also a real boost for life sciences in Wales.
“These strong Pisces II results follow on from all of the positive safety and efficacy data accumulated over the last three years from the Pisces 1 study. “